Hausheer, F., Kochat, H., Seetharamulu, P., Yao, S., Ding, D., Huang, Q., Chen, X., Zhao, A., Hamilton, S., Petluru, P., Wu, M., Ma, H., Wang, J., Wu, Y., Leverett, B., Saxe, J., Parker, A., Berghorn, E. BNP1350's Superior Molecular Characteristics: Enhanced Therapeutic Performance of Novel, Lipophilic, Lactone Stable Camptothecin Analogues. Presented at 2001 AACR Meeting, Abstract Number 559.
Hausheer, F., Kochat, H., Zhao, A., Hamilton, S., Wu, J., Seetharamulu, P., Yao, S., Petluru, P., Huang, Q., Chen, X., Ma, H., Ding, D., Leverett, B., Wu, Y., Wang, J., Saxe, J., Parker, A., Berghorn, E. BNP7787 a Novel Neuroprotective Agent in Taxane and Platinum Regimens Does Not Interfere with Antitumor Activity. Presented at 2001 AACR Meeting, Abstract Number 1990.
Keir, S.T., Hausheer, F., Lawless, A.A., Bigner, D.D., Friedman, H.S. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother. Pharmacol., 48(1): 83-7, 2001.
Maliepaard, M., van Gastelen, M.A., Tohgo, A., Hausheer, F.H., van Waardenburg, R.C., de Jong, L.A., Pluim, D., Beijnen, J.H., Schellens, J.H. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res., 7(4): 935-41, 2001.
Smith, J.A., Hausheer, F., Newman, R.A., Madden, T.L. Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine. J. Chromatogr. B Biomed. Sci. Appl., 759(1): 117-24, 2001.Chaudhuri, A.R., Seetharamalu, P., Schwarz, P.M., Hausheer, F.H., Luduena, R.F. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach. J. Mol. Biol., 303(5): 679-92, 2000.
Hausheer, F., Kochat, H., Zhao, M., Murali, D., Seetharamulu, P., Yao, S., Reddy, D., Pavankumar, P., Saxe, J., Huang, Q., Chen, X., Parker, A., Wu, M., Hamilton, S., Berghorn, E. Karenitecins: Further Developments with BNP1350: A Novel, Highly Lipophilic, Lactone Stable Camptothecin. Presented at 2000 AACR Meeting, Abstract Number 1360.
Hausheer, F., Kochat, H., Reddy, D., Zhao, M., Seetharamulu, P., Yao, S., Pavankumar, P., Murali, D., Wu, M., Saxe, J., Parker, A., Hamilton, S., Huang, Q., Chen, X., and Berghorn, E. BNP7787: A Novel Chemoprotecting Agent for Platinum and Taxane Toxicity. Presented at 2000 AACR Meeting, Abstract Number 4890.
Schilsky, R.L., Hausheer, F.H., Bertucci, D., Berghorn, E., Kindler, H.L. and Ratain, M.J. Phase I Trial Of Karenitecin Administered Intravenously Daily For Five Consecutive Days In Patients With Advanced Solid Tumors Using Accelerated Dose Titration. Presented at 2000 ASCO Meeting, Abstract Number 758.
Van Hattum, A.H., Pinedo, H.M., Schluper, H.M., Hausheer, F.H., Boven, E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer, 88(2): 260-6, 2000.
Zukowski, T., Madden, T.L., Hoff, P.M., Newman, R.A., Ravandi, F., Medgyesy, D., Carter, S., Brito, R., Berghorn, E., Hausheer, F., Pazdur, R. Phase I and Pharmacokinetic Trial of the Antifolate (g)-Methylene-10-Deazaaminopterin (MDAM) in Patients with Advanced Solid Tumors. 2000 ASCO Meeting, Abstract Number 759.Cavalletti, E., Cavaletti, G., Tredici, G., Oggioni, N., Spinelli, S., Reddy, D., Yao, S., Parker, A., Zhao, M., Wu, M., Haridas, K., Seetharamulu P., and Hausheer, F. Oral and Intravenous BNP7787 Protects Against Paclitaxel-Mediated Neurotoxicity in Wistar Rats. Presented at 1999 AACR Meeting Abstract Number 2632.
Hausheer, F., Cao, S., Kanter, P., Haridas, K., Zhao, M., Murali, D., Seetharamulu, P., Yao, S., Reddy, D., Pavankumar, P., Saxe, J., Huang, Q., Chen, X., Parker, A., Wu, M., Martinez, N., Rustum, Y. Karenitecins: New Preclinical Developments with BNP1350; A Novel, Potent Highly Lipophilic Camptothecin. Presented at 1999 AACR Meeting, Abstract Number 741.
Hausheer, F., Cavalletti, E., Cavaletti, G., Tredici, G., Oggioni, N., Spinelli, S., Pezzoni, G., Manzotti, C., Parker, A., Haridas, K., Reddy, D., Seetharamulu, P., Zhao, M., Yao, S., Pavankumar, P. and Murali, D. Oral and Intravenous BNP7787 Protects Against Platinum Neurotoxicity Without In Vitro or In Vivo Tumor Protection. Presented at 1999 AACR Meeting, Abstract Number 2633.
Matsui, S., Endo, W., Wrzosek, C., Haridas, K., Seetharamulu, P., Hausheer, F.H., Rustum, Y.M. Characterization of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications. Eur. J. Cancer, 35(6): 984-93, 1999.
Pavankumar, P.N.V., Seetharamulu, S., Yao, S., Saxe, J.D., Reddy, D.G., Hausheer, F.H. Comprehensive Ab Initio Quantum Mechanical and Molecular Orbital (MO) Analysis of Cisplatin: Structure, Bonding, Charge Density, and Vibrational Frequencies. Journal of Computational Chemistry, 20(3): 365-382, 1999.
Schilsky, R.L., Schwartz, G.N., Berghorn, E., Bertucci, D., Ratain, M., Zukiwski, A., and Hausheer, F. Phase I Trial of Escalating Doses of BNP7787 in Patients Receiving Cisplatin (CDDP) and Paclitaxel (TAX). Presented at 1999 ASCO Meeting, Abstract Number 647.Hausheer, F.H., Kanter, P., Cao, S., Haridas, K., Seetharamulu, P., Reddy, D., Petluru, P., Zhao, M., Murali, D., Saxe, J.D., Yao, S., Martinez, N., Zukowski, A., Rustum, Y.M. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin. Oncol., 25(5): 584-99, 1998.
Hausheer, F., Kanter, P., Rustum, Y., Cao, S., Haridas, K., Reddy, D., Seetharamulu, P., Zhao, M., Yao, S., Pavankumar, P. and Murali, D. BNP7787 - Administration IN VIVO Results in Increased Therapeutic Index and Toxicity Reduction of Platinum Drugs. Presented at 1998 AACR Meeting, Abstract Number 1077.
Hausheer, F.H., Haridas, K., Zhao, M., Murali, D., Seetharamulu, P., Yao, S., Reddy, D., Pavankumar, P., Wu, M., Saxe, J., Huang, Q., and Rustum, Y. Karenitecins (Part II): A Novel Class of Orally Active Highly Lipophilic Topoisomerase I Inhibitors. Presented at 1998 AACR Meeting, Abstract Number 2862.
Shulman-Roskes, E.M., Noe, D.A., Gamcsik, M.P., Marlow, A.L., Hilton, J., Hausheer, F.H., Colvin, O.M., Ludeman, S.M. The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions. J. Med. Chem., 41(4): 515-29, 1998.
Yao, S., Murali, D., Seetharamulu, P., Haridas, K., Petluru, P.N., Reddy, D.G., Hausheer, F.H. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res., 58(17): 3782-6, 1998.
Hausheer, F.H., Jones, N.D., Seetharamulu, P., Singh, U.C., Deeter, J.B., Hertel, L.W., Kroin, J.S. Ab initio quantum mechanical and X-ray crystallographic studies of gemcitabine and 2'-deoxy cytosine. Comp. Chem., 20(4): 459-67, 1996.